<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04484155</url>
  </required_header>
  <id_info>
    <org_study_id>MMS-072-51</org_study_id>
    <nct_id>NCT04484155</nct_id>
  </id_info>
  <brief_title>Minimally Invasive Micro Sclerostomy: Safety and Preliminary Performance Study</brief_title>
  <official_title>Minimally Invasive Micro Sclerostomy: First in Man (FIM) Safety and Preliminary Performance Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanoculis Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanoculis Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eligible Glaucoma patients will undergo pre-surgery examination including:&#xD;
&#xD;
      medicines list, blood tests and ECG. On surgery day: intraocular pressure (IOP) will be&#xD;
      measured. Then a sub-conjunctival injection of Mitomycin C will be administered .&#xD;
&#xD;
      The Minimally Invasive Micro Sclerostomy (MIMS) procedure is designed to create a drainage&#xD;
      channel at the sclera-corneal junction by penetrating through the wall [scleral tissue] .&#xD;
      MIMS procedure may be combined with cataract surgery.&#xD;
&#xD;
      Patients will be followed up to 24 weeks post operation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible patients will have ECG and blood test up to 30 days prior to the MIMS procedure.&#xD;
&#xD;
      Description of MIMS procedure:&#xD;
&#xD;
      on surgery day, intraocular pressure (IOP) will be measured. Then a sub-conjunctival&#xD;
      injection of Mitomycin C will be administered .&#xD;
&#xD;
      creating drainage channel at the sclera-corneal junction by penetrating through the wall&#xD;
      [scleral tissue].MIMS procedure may be combined with cataract surgery.&#xD;
&#xD;
      Post-operatively the patient will be treated with dexamethasone-neomycin drops for at least&#xD;
      one month.&#xD;
&#xD;
      Patients will be followed up to 24 weeks post operation.&#xD;
&#xD;
      The following measurements will be included:&#xD;
&#xD;
        -  Intra Ocular Pressure (IOP)&#xD;
&#xD;
        -  Best Corrected Visual Acuity (BCVA)&#xD;
&#xD;
        -  Slit Lamp Biomicroscopic evaluation&#xD;
&#xD;
        -  Anterior Segment Optical coherence tomography (OCT)&#xD;
&#xD;
        -  Fundus Examination&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 16, 2018</start_date>
  <completion_date type="Actual">March 5, 2020</completion_date>
  <primary_completion_date type="Actual">March 2, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serious Adverse Event</measure>
    <time_frame>12 weeks</time_frame>
    <description>Overall incidence of serious adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Drainage Channel Creation</measure>
    <time_frame>Index procedure day</time_frame>
    <description>Ability to successfully perform a drainage channel</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Event</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Overall incidence of serious adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure</measure>
    <time_frame>24 Weeks</time_frame>
    <description>Intraocular Pressure between 6 mmHg and 20 mmHg</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Minimally invasive micro sclerostomy (MIMS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>create a drainage channel at the sclera-corneal junction</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Minimally Invasive Micro Sclerostomy (MIMS)</intervention_name>
    <description>The System is a surgical device, designed to create a drainage channel at the sclera-corneal junction . The drainage channel is created by a Stainless Steel surgical tool.</description>
    <arm_group_label>Minimally invasive micro sclerostomy (MIMS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female ≥ 18 years&#xD;
&#xD;
          -  End stage Primary open-angle glaucoma,pseudoexfoliation glaucoma or pigmentary&#xD;
             glaucoma in the study eye&#xD;
&#xD;
          -  Optic nerve appearance characteristic of glaucoma in the study eye&#xD;
&#xD;
          -  Best-corrected visual acuity (BCVA) with ETDRS charts ≤ 6/60&#xD;
&#xD;
          -  Patient is treated with 0 to 5 hypotensive medications in the study eye&#xD;
&#xD;
          -  Unsatisfactory IOP (≥ 21 mmHg) at the screening visit in the study eye&#xD;
&#xD;
          -  If cataract is not present - Shaffer grade ≥ III in all four angle quadrants in the&#xD;
             study eye&#xD;
&#xD;
          -  Subject is able and willing to attend all scheduled follow-up exams&#xD;
&#xD;
          -  Subject understands and signs the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Ocular conditions with a poorer prognosis in the fellow eye than in the study eye&#xD;
&#xD;
          -  Closed angle forms of glaucoma in either eye unless scheduled for cataract surgery&#xD;
             immediately prior to the MIMS procedure or the study eye is pseudophakic with PCIOL.&#xD;
&#xD;
          -  Congenital or developmental glaucoma in either eye&#xD;
&#xD;
          -  Other secondary glaucoma (such as neovascular, uveitic, lens-induced, trauma-induced,&#xD;
             or glaucoma associated with increased episcleral venous pressure) in the study eye&#xD;
&#xD;
          -  Peripheral anterior synechiae (PAS), rubeosis or other angle abnormalities in the&#xD;
             study eye&#xD;
&#xD;
          -  Subject has history of penetrating keratoplasty (PKP)&#xD;
&#xD;
          -  Any previous surgery in the study eye (except for clear corneal cataract surgery)&#xD;
             where the conjunctiva is not intact and elastic.&#xD;
&#xD;
          -  Any ocular disease or history in study eye such as severe dry eye, active&#xD;
             proliferative retinopathy, ICE syndrome, epithelial or fibrous down growth, and ocular&#xD;
             pathology that may interfere with accurate IOP measurements&#xD;
&#xD;
          -  Prior surgery for an ab-interno or ab-externo device implanted in or through the&#xD;
             Schlemm's canal in the study eye.&#xD;
&#xD;
          -  Use of oral hypotensive medication for glaucoma for treatment of the fellow eye&#xD;
&#xD;
          -  Best-corrected visual acuity worse than 20/50 (Snellen equivalent) in the fellow eye&#xD;
&#xD;
          -  History of idiopathic or autoimmune uveitis in either eye&#xD;
&#xD;
          -  Severe trauma in study eye&#xD;
&#xD;
          -  active iris neovascularization, previous cyclodestructive procedure, prior scleral&#xD;
             buckling procedure, presence of silicone oil&#xD;
&#xD;
          -  Vitreous present in anterior chamber, prior vitrectomy or virteous hemorrhage in study&#xD;
             eye&#xD;
&#xD;
          -  Aphakia&#xD;
&#xD;
          -  Prior vitreoretinal surgery in study eye&#xD;
&#xD;
          -  Clinically significant ocular inflammation or infection within 90 days prior to&#xD;
             screening&#xD;
&#xD;
          -  Unable to discontinue use of blood thinners in accordance with surgeon's standard&#xD;
             preoperative instructions&#xD;
&#xD;
          -  Uncontrolled systemic disease that in the opinion of the investigator would put the&#xD;
             subject's health at risk and/or prevent the subject from completing all study visits&#xD;
&#xD;
          -  Current participation or participation in another investigational drug or device&#xD;
             clinical trial within the last 30 days before screening visit&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dr. Agarwal Eye Hospital Ltd.</name>
      <address>
        <city>Chennai</city>
        <zip>600086</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>July 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2020</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

